Skip to main content
DGX logo

Quest Diagnostics Incorporated (DGX) Stock: Price, Forecast & Analyst Target

Quest Diagnostics Incorporated (DGX) — MoonshotScore 74/100 (Strong band), calculated Nov 18, 2026. Price $258.99 (-0.27%), as of the Nov 19, 2026 trading session; market cap $28.5B. Expected results Feb 9, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$258.99 −$0.705 (-0.27%) Market Cap $28.5B

Quest Diagnostics Incorporated · DGX · NYSE · Healthcare · Medical Diagnostics & Research

Research dated 2026-09-12: Quest Diagnostics turns patient specimens and clinical encounters into testing results, diagnostic information and related services for clinicians, hospitals, health plans, employers and patients. The case depends on whether rising demand through its laboratory and collection network can keep lifting profit and cash generation while a debt-heavy balance sheet limits room for disappointment.

Price as of Nov 19, 2026

Key Statistics

74 of 100

MoonshotScore v2 · Quest Diagnostics (DGX)

Strong
Business Quality Solid (79)
Financial Safety Okay (47)
Valuation Fair (60)
Growth Durability Flat (50)
Momentum Surging (90)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 8 of the last 8 reports
  • expected results Feb 9, 2027
  • Altman Z 3.81 · Piotroski F 7

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DGX (57 recorded, newest six shown)
RecordedScoreBand
75Strong
76Strong
76Strong
76Strong
74Strong
74Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$258.99
Change on the day-0.27%
52-week range$171.18–$263.19
Market capitalisation$28.5B—
Price / earnings (trailing)25.18
Shares traded on the day892.4K
Beta (volatility vs the S&P 500)0.55

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $174, high $260, latest $259. $260 $174 high $260 Oct 17, 2025 Nov 19, 2026 · $259 $190Oct 17, 2025$176Oct 31, 2025$187Nov 14, 2025$189Nov 28, 2025$183Dec 12, 2025$176Dec 26, 2025$174Jan 9, 2026$181Jan 23, 2026$191Feb 6, 2026$202Feb 20, 2026$199Mar 6, 2026$195Mar 20, 2026$198Apr 2, 2026$195Apr 17, 2026$193May 1, 2026$187May 15, 2026$195May 29, 2026$203Jun 12, 2026$210Jun 26, 2026$207Jul 10, 2026$228Jul 24, 2026$238Aug 7, 2026$244Aug 21, 2026$237Sep 4, 2026$246Sep 18, 2026$233Oct 2, 2026$235Oct 16, 2026$252Oct 30, 2026$260Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Quest Diagnostics (DGX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Moderate
Growth Durability Neutral
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Moderate
Debt/Equity Weak
ROE Moderate
Gross Margin Neutral

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens, Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Quest Diagnostics (DGX), and what does it report?

Short answer · as of

Quest sells routine and advanced clinical testing, anatomic pathology, diagnostic information and related services.

Its delivery system spans laboratories, patient service centers, in-office phlebotomists and mobile health professionals, while specialized brands serve pathology, insurance risk assessment and healthcare technology needs.

Reported revenue is overwhelmingly concentrated in Diagnostic Information Services. That makes test activity and the economics of collecting, processing and reporting results more important than the broad healthcare classification might suggest; this is primarily a scaled service network, not a drug-development pipeline.

2 · Latest results

What do the latest results show for Quest Diagnostics (DGX)?

The latest period extended a broad operating advance: revenue, gross profit, operating income, net income and diluted earnings all rose from the preceding period. Operating cash flow also strengthened, while reported revenue and earnings continued their run above consensus expectations.

Management attributed the raised full-year outlook to growth momentum and continued interest in its lab insights. That explanation is management’s framing rather than a disclosed bridge from test volume, pricing or acquisitions, so the reported profit progression remains the firmer evidence.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$2.82B$245M$2.15 (diluted)
Q4 FY2025$2.81B$245M$2.19 (diluted)
Q1 FY2026$2.90B$252M$2.24 (diluted)
Q2 FY2026$3.04B$320M$2.85 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Quest Diagnostics (DGX)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Quest consistently generated operating cash after capital spending across the reported quarterly series, and the latest period paired stronger operating cash flow with a higher cash balance. Liquidity ratios also indicate near-term resources exceed near-term obligations, while profitability and quality screens remain constructive.

The constraint is leverage. Debt substantially exceeds cash and investments, and cash remains below its level at the opening of the reported window despite the recent rebound. A revenue shortfall linked to reimbursement or coverage pressure would therefore matter beyond the income statement by reducing financial flexibility; management already assumes an exchange-subsidy expiration will weigh on revenue.

4 · What to check next?

What should you watch next at Quest Diagnostics (DGX)?

Short answer · as of

The next earnings report is expected on Feb 9, 2027.

Watch whether revenue can hold near its recent high while operating income and net income preserve their latest step upward. Cash conversion after capital spending is the useful cross-check: another strong accounting result accompanied by weaker operating cash would deserve scrutiny.

The scheduled earnings release should also clarify whether management’s raised outlook remains supported and whether the assumed exchange-subsidy drag is developing as expected. Separately, progress on the planned Michigan laboratory joint venture would test the stated launch timetable.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Quest Diagnostics compare with its peers?

Short answer

Quest Diagnostics's score ranks 5th of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Quest differs from businesses whose value rests on a narrow diagnostic product or research pipeline. It monetizes a broad testing and information network across patients, clinicians, hospitals, health plans, employers and insurers, with collection infrastructure and specialized brands extending its reach.

That breadth makes network throughput, service economics and cash conversion the relevant comparison points. Revenue concentration in Diagnostic Information Services also means the adjacent technology and insurance offerings diversify customer use cases more than they diversify the reported revenue base.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
United Therapeutics Corporation (UTHR) Named competitor$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Medpace Holdings, Inc. (MEDP) Named competitor$646.87 Nov 18, 2026$18.1B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Named competitor$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Named competitor$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Quest Diagnostics (DGX) — this page$258.99$28.5B74
Labcorp Holdings Inc. (LH) Named competitor$370.78 Nov 18, 2026$30.1B71 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$245.00 – $262.00
Consensus target
$256.17
Median target
$260.00

Consensus record · Captured .

Measured against a quoted price of $258.99 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 13, 2026

Transactions
57
Identified insiders
15
Purchases
0
Sales
18
Other transactions
39

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DGX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DGX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Quest Diagnostics (DGX) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What does Quest Diagnostics sell beyond routine laboratory tests?

Quest also provides advanced clinical and anatomic pathology testing, diagnostic information, insurance risk assessment and healthcare technology services through brands including AmeriPath, Dermpath Diagnostics, ExamOne and Quanum.

What is Quest Diagnostics planning for its Michigan laboratory operation?

Management said it expects to build the Michigan laboratory into a joint venture and is targeting a launch in the coming year. Progress against that timetable is the concrete item to monitor.

Why does the exchange-subsidy expiration matter to Quest Diagnostics?

Management has incorporated an expected revenue drag from the subsidy expiration into its outlook. The next earnings update can show whether that assumption remains appropriate or requires revision.

Has Quest Diagnostics maintained its recently increased dividend?

The declared upcoming payment matches the latest paid amount, which was above the earlier run rate. That establishes continuity at the increased level without indicating what later declarations may be.

What is the DGX stock price today?

The last price recorded for Quest Diagnostics Incorporated (DGX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the DGX price target?

The analyst consensus price target for Quest Diagnostics Incorporated (DGX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is Quest Diagnostics (DGX), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment
  • 2. What do the latest results show for Quest Diagnostics (DGX)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Quest Diagnostics (DGX)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Management outlook — dated call excerpts
  • 4. What should you watch next at Quest Diagnostics (DGX)?: Next earnings report; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 5. How does Quest Diagnostics compare with its peers?: Business description; Employees; Revenue by segment; Trailing twelve-month ratio set
  • FAQ: What does Quest Diagnostics sell beyond routine laboratory tests?: Business description
  • FAQ: What is Quest Diagnostics planning for its Michigan laboratory operation?: Management outlook — dated call excerpts
  • FAQ: Why does the exchange-subsidy expiration matter to Quest Diagnostics?: Management outlook — dated call excerpts; Next earnings report
  • FAQ: Has Quest Diagnostics maintained its recently increased dividend?: Next scheduled dividend; Recent dividends paid
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold DGX

Funds in our ETF coverage that list DGX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
IHF ETF3.98%
XHS ETF2.33%